Outlook Therapeutics
OTLK
66 hedge funds and large institutions have $44.7M invested in Outlook Therapeutics in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 7 closing their positions.
1,854% more call options, than puts
Call options by funds: $1.64M | Put options by funds: $84K
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
3% more funds holding
Funds holding: 64 → 66 (+2)
0.87% less ownership
Funds ownership: 36.28% → 35.41% (-0.87%)
29% less capital invested
Capital invested by funds: $62.7M → $44.7M (-$17.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.79M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$826K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$669K |
| 5 |
ACM
Altium Capital Management
New York
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.99M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.82M |
| 3 |
CP
Caligan Partners
New York
|
-$1.33M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.16M |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$663K |
OTLK Hedge Fund Activity: Q3 2024 in Review
66 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2024, worth a combined $44.7M — down 29% from $62.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OTLK positions and 7 closed out — a net gain of 3 holders — while 27 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $2.79M. The largest seller was Great Point Partners, cutting an estimated $2.99M.
- 66 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2024, up from 64 in Q2 2024.
- Funds reported $44.7M of Outlook Therapeutics stock for Q3 2024, down 29% quarter-over-quarter.
- 10 funds opened new Outlook Therapeutics positions in Q3 2024 and 7 closed out, a net change of +3 holders.
- The largest Outlook Therapeutics buyer in Q3 2024 was BlackRock, an estimated $2.79M added.
- The largest Outlook Therapeutics seller in Q3 2024 was Great Point Partners, an estimated $2.99M sold.
Based on aggregated 13F filings for Q3 2024.